PDF(Pubmed)
Abstract：
Nipah virus (NiV), a bat-borne paramyxovirus, results in neurological and respiratory diseases with high mortality in humans and animals. Developing vaccines is crucial for fighting these diseases. Previously, only a few studies focused on the fusion (F) protein alone as the immunogen. Numerous NiV strains have been identified, including 2 representative strains from Malaysia (NiV-M) and Bangladesh (NiV-B), which differ significantly from each other. In this study, an F protein sequence with the potential to prevent different NiV strain infections was designed by bioinformatics analysis after an in-depth study of NiV sequences in GenBank. Then, a chimpanzee adenoviral vector vaccine and a DNA vaccine were developed. High levels of immune responses were detected after AdC68-F, pVAX1-F, and a prime-boost strategy (pVAX1-F/AdC68-F) in mice. After high titers of humoral responses were induced, the hamsters were challenged by the lethal NiV-M and NiV-B strains separately. The vaccinated hamsters did not show any clinical signs and survived 21 days after infection with either strain of NiV, and no virus was detected in different tissues. These results indicate that the vaccines provided complete protection against representative strains of NiV infection and have the potential to be developed as a broad-spectrum vaccine for human use.
摘要：
尼帕病毒(NiV),蝙蝠传播的副粘病毒,导致神经系统和呼吸系统疾病，在人类和动物中死亡率很高。开发疫苗对疾病至关重要。先前的一些研究集中于单独的融合(F)蛋白作为免疫原。已经鉴定出许多NiV菌株，包括来自马来西亚（NiV-M）和孟加拉国（NiV-B）的两个代表性菌株，这与另一个有很大不同。在这项研究中,在GenBank中对NiV序列进行深入研究后，通过生物信息学分析设计了具有预防不同NiV菌株感染潜力的F蛋白序列。然后，开发了黑猩猩腺病毒载体疫苗和DNA疫苗。AdC68-F检测到高水平的免疫反应，pVAX1-F和小鼠中的初免-加强策略(pVAX1-F/AdC68-F)。在诱导高滴度的体液反应后，仓鼠受到致命的NiV-M和NiV-B菌株的攻击，分别。令人放心的是，接种疫苗的仓鼠没有显示任何临床症状，并且在感染任一NiV菌株后存活21天，在不同的组织中也没有检测到病毒。这些结果表明,疫苗提供针对NiV感染的代表性毒株的完全保护,并且具有被开发为人类使用的广谱疫苗的潜力。
